View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
June 1, 2020

Chemokine inhibitors in the bullous pemphigoid pipeline may be the safest treatment for refractory patients

By Victoria Smith

Bullous pemphigoid is an autoimmune skin condition characterised by boils, rashes, and blisters, as well as prolonged inflammation and pruritus. The condition is painful, typically occurring in patients with ailments such as hypertension, diabetes, heart disease, and other autoimmune diseases such as lupus and rheumatoid arthritis.

Its pathology involves the formation of autoantibodies that target dystonin, a protein that is part of the plakin family associated with the cytoskeleton and multiprotein complexes at cell junctions. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology